Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes

被引:768
作者
Basta, G
Schmidt, AM
De Caterina, R
机构
[1] CNR, Inst Clin Physiol, I-56100 Pisa, Italy
[2] Columbia Univ, New York, NY USA
[3] Univ G DAnnunzio, Inst Cardiol, Osped S Camillo Lellis, I-66100 Chieti, Italy
[4] Univ G DAnnunzio, Ctr Excellence Aging, Osped S Camillo Lellis, I-66100 Chieti, Italy
关键词
advanced glycation end products; atherosclerosis; inflammation; diabetes; endothelium;
D O I
10.1016/j.cardiores.2004.05.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The formation of advanced glycation end products (AGEs) is an important biochemical abnormality that accompanies diabetes mellitus, and, likely, inflammation in general. Here we summarize and discuss recent studies indicating that the effects of AGEs on vessel wall homeostasis may account for the rapidly progressive atherosclerosis associated with diabetes mellitus. Driven by hyperglycemia and oxidant stress, AGEs form to a greatly accelerated degree in diabetes. Within the vessel wall, collagen-linked AGEs may "trap" plasma proteins, quench nitric oxide (NO) activity and interact with specific receptors to modulate a large number of cellular properties. On plasma low density lipoproteins (LDL), AGEs initiate oxidative reactions that promote the formation of oxidized LDL. Interaction of AGEs with endothelial cells, as well as with other cells accumulating within the atherosclerotic plaque, such as mononuclear phagocytes and smooth muscle cells (SMCs), provides a mechanism to augment vascular dysfunction. Specifically, the interaction of AGEs with vessel wall components increases vascular permeability, the expression of procoagutant activity and the generation of reactive oxygen species (ROS), resulting in increased endothelial expression of endothelial leukocyte adhesion molecules. AGEs potently modulate initiating steps in atherogenesis involving blood-vessel wall interactions, triggering an inflammatory-proliferative process and, furthermore, critically contribute to propagation of inflammation and vascular perturbation in established disease. Thus, a better understanding of the biochemical mechanisms by which AGEs contribute to such processes in the vessel wall could be relevant to devise preventive and therapeutic strategies for diabetic atherosclerosis. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:582 / 592
页数:11
相关论文
共 98 条
  • [11] ADVANCED GLYCOSYLATION PRODUCTS QUENCH NITRIC-OXIDE AND MEDIATE DEFECTIVE ENDOTHELIUM-DEPENDENT VASODILATATION IN EXPERIMENTAL DIABETES
    BUCALA, R
    TRACEY, KJ
    CERAMI, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (02) : 432 - 438
  • [12] RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice
    Bucciarelli, LG
    Wendt, T
    Qu, W
    Lu, Y
    Lalla, E
    Rong, LL
    Goova, MT
    Moser, B
    Kislinger, T
    Lee, DC
    Kashyap, Y
    Stern, DM
    Schmidt, AM
    [J]. CIRCULATION, 2002, 106 (22) : 2827 - 2835
  • [13] LAMININ ALTERATIONS AFTER INVITRO NONENZYMATIC GLYCOSYLATION
    CHARONIS, AS
    REGER, LA
    DEGE, JE
    KOUZIKOLIAKOS, K
    FURCHT, LT
    WOHLHUETER, RM
    TSILIBARY, EC
    [J]. DIABETES, 1990, 39 (07) : 807 - 814
  • [14] The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment
    Chavakis, T
    Bierhaus, A
    Al-Fakhri, N
    Schneider, D
    Witte, S
    Linn, T
    Nagashima, M
    Morser, J
    Arnold, B
    Preissner, KT
    Nawroth, PP
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (10) : 1507 - 1515
  • [15] The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques - Role of glycemic control
    Cipollone, F
    Iezzi, A
    Fazia, M
    Zucchelli, M
    Pini, B
    Cuccurullo, C
    De Cesare, D
    De Blasis, G
    Muraro, R
    Bei, R
    Chiarelli, F
    Schmidt, AM
    Cuccurullo, F
    Mezzetti, A
    [J]. CIRCULATION, 2003, 108 (09) : 1070 - 1077
  • [16] Multifactorial aspects of the treatment of the type II diabetic patient
    Colwell, JA
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (12): : 1 - 4
  • [17] The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
    Cooper, ME
    Thallas, V
    Forbes, J
    Scalbert, E
    Sastra, S
    Darby, I
    Soulis, T
    [J]. DIABETOLOGIA, 2000, 43 (05) : 660 - 664
  • [18] ENDOTHELIAL EXPRESSION OF A MONONUCLEAR LEUKOCYTE ADHESION MOLECULE DURING ATHEROGENESIS
    CYBULSKY, MI
    GIMBRONE, MA
    [J]. SCIENCE, 1991, 251 (4995) : 788 - 791
  • [19] De C.R., 1995, J CLIN INVEST, V96, P60
  • [20] Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139